《组蛋白去乙酰化酶抑制剂chidamide治疗多发性骨髓瘤溶骨性病变的机制研究》解读

Comments on “Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease”

本文最初发表于2018年《Haematologica》杂志上,文章题录为:He J,Chen Q,Gu H,et al.Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease[J].Haematologica,2018,103:1369-1379。在本研究中,我们发现组蛋白去乙酰化酶抑制剂chidamide不仅诱导骨髓瘤细胞凋亡,抑制骨髓瘤细胞生长,同时可以调节骨髓瘤骨髓微环境,抑制破骨细胞的分化发育,减轻骨髓瘤溶骨性病变的发生,为骨髓瘤的治疗提供新的视角。